Simcere Pharmaceutical Group - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Simcere Pharmaceutical Group - Product Pipeline Review - 2014" provides data on the Simcere Pharmaceutical Group's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Simcere Pharmaceutical Group's corporate website, SEC filings, investor presentations and featured press releases, both from Simcere Pharmaceutical Group and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Simcere Pharmaceutical Group - Brief Simcere Pharmaceutical Group overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Simcere Pharmaceutical Group human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Simcere Pharmaceutical Group with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Simcere Pharmaceutical Group's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Simcere Pharmaceutical Group's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Simcere Pharmaceutical Group in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Simcere Pharmaceutical Group's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Simcere Pharmaceutical Group.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Simcere Pharmaceutical Group and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Simcere Pharmaceutical Group Snapshot 6
Simcere Pharmaceutical Group Overview 6
Key Information 6
Key Facts 6
Simcere Pharmaceutical Group - Research and Development Overview 7
Key Therapeutic Areas 7
Simcere Pharmaceutical Group - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Simcere Pharmaceutical Group - Pipeline Products Glance 15
Simcere Pharmaceutical Group - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Simcere Pharmaceutical Group - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Simcere Pharmaceutical Group - Early Stage Pipeline Products 18
IND/CTA Filed Products/Combination Treatment Modalities 18
Preclinical Products/Combination Treatment Modalities 19
Simcere Pharmaceutical Group - Drug Profiles 20
bendamustine hydrochloride 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Recombinant Human Endostatin + [cisplatin] + [vinorelbine tartrate] 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
fluorouracil 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(irbesartan + amlodipine) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
APX-003 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
SIM-071201 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Simotinib Hydrochloride 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
BMS-817378 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
OSI-930 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SIM-010603 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SIM-0710 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BMS-795311 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SIM-89 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Simcere Pharmaceutical Group - Pipeline Analysis 33
Simcere Pharmaceutical Group - Pipeline Products by Therapeutic Class 33
Simcere Pharmaceutical Group - Pipeline Products by Target 35
Simcere Pharmaceutical Group - Pipeline Products by Route of Administration 37
Simcere Pharmaceutical Group - Pipeline Products by Molecule Type 38
Simcere Pharmaceutical Group - Pipeline Products by Mechanism of Action 39
Simcere Pharmaceutical Group - Recent Pipeline Updates 41
Simcere Pharmaceutical Group - Dormant Projects 44
Simcere Pharmaceutical Group - Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Simcere Pharmaceutical Group, Key Information 6
Simcere Pharmaceutical Group, Key Facts 6
Simcere Pharmaceutical Group - Pipeline by Indication, 2014 9
Simcere Pharmaceutical Group - Pipeline by Stage of Development, 2014 10
Simcere Pharmaceutical Group - Monotherapy Products in Pipeline, 2014 11
Simcere Pharmaceutical Group - Combination Treatment Modalities in Pipeline, 2014 12
Simcere Pharmaceutical Group - Partnered Products in Pipeline, 2014 13
Simcere Pharmaceutical Group - Partnered Products/ Combination Treatment Modalities, 2014 14
Simcere Pharmaceutical Group - Phase III, 2014 15
Simcere Pharmaceutical Group - Phase II, 2014 16
Simcere Pharmaceutical Group - Phase I, 2014 17
Simcere Pharmaceutical Group - IND/CTA Filed, 2014 18
Simcere Pharmaceutical Group - Preclinical, 2014 19
Simcere Pharmaceutical Group - Pipeline by Therapeutic Class, 2014 34
Simcere Pharmaceutical Group - Pipeline by Target, 2014 36
Simcere Pharmaceutical Group - Pipeline by Route of Administration, 2014 37
Simcere Pharmaceutical Group - Pipeline by Molecule Type, 2014 38
Simcere Pharmaceutical Group - Pipeline Products by Mechanism of Action, 2014 40
Simcere Pharmaceutical Group - Recent Pipeline Updates, 2014 41
Simcere Pharmaceutical Group - Dormant Developmental Projects,2014 44
Simcere Pharmaceutical Group, Subsidiaries 45